Pharmacogenomics in dermatology;Pharmakogenomik in der dermatologie

JDDG - Journal of the German Society of Dermatology

Volumn 3, Issue 3, 2005, Pages 214-222

  Harr, Thomas ^a   Itin, Peter H ^a  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; ERYTHROMYCIN; ITRACONAZOLE; KETOCONAZOLE; LINCOSAMIDE; MIKAMYCIN B; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AUTOIMMUNE DISEASE; CYTOLOGY; DERMATOLOGY; DNA MICROARRAY; DRUG METABOLISM; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MELANOMA; PHARMACOGENOMICS; REVIEW; SKIN INFECTION;

EID: 14944371141     PISSN: 16100379     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1610-0378.2005.04535.x     Document Type: Review

References (32)

1. Reszka E, Wasowicz W. Genetic polymorphism of N-acetyltransferase and glutathione S-transferase related to neoplasm of genitourinary system. Minireview. Neoplasma 2002; 49: 209-216.
2. Wang CY, Jones RF, Debiec-Rychter M, Soos G, Haas GP. Correlation of the genotypes for N-acetyltransferases 1 and 2 with double bladder and prostate cancers in a case-comparison study. Anticancer Res 2002; 22: 3529-3535.
3. Biollaz J, Dayer P, Galeazzi RL, Gysling E, Krähenbühl S, Lauterburg B, Meier-Abt P. Grundlagen der Arzneimitteltherapie. Documed Basel 2001.
4. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 2001; 482: 11-19.
5. Miller MC 3rd, Mohrenweiser HW, Bell DA. Genetic variability in susceptibility and response to toxicants. Toxicol Lett 2001; 120: 269-280.
6. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 2002; 181-182: 447-452.
7. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25: 193-200.
8. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-263.
9. Stark K, Törmä H, Cristea M, Oliw EH. Expression of CYP4F8 (prostaglandin H 19-hydroxylase) in human epithelia and prominent induction in epidermis of psoriatic lesions. Arch Biochem Biophys 2003; 409: 188-196.
10. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828-1837.
11. Zhang CL, Kamarashev J, Qin JZ, Burg G, Dummer R, Dobbeling U. Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells. J Pathol 2003; 200: 249-254.
12. Tracey L, Villuendas R, Ortiz P, Dopazo A, Spiteri I, Lombardia L, Rodriguez-Peralto JL, Fernandez-Herrera J, Hernandez A, Fraga J, Dominguez O, Herrero J, Alonso MA, Dopazo J, Piris MA. Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am J Pathol 2002; 161: 1825-1837.
13. Fulda S, Debatin KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004; 64: 337-346.
14. Iida J, Wilhelmson KL, Price MA, Wilson CM, Pei D, Furcht LT, McCarthy JB. Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J Invest Dermatol 2004; 122: 167-176.
15. Cavert W, Balfour HH Jr. Detection of antiretroviral resistance in HIV-1. Clin Lab Med 2003; 23: 915-928.
16. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50: 1378-1388.
17. Caron M, Auclair M, Sterlingot H, Kornprobst M, Capeau J. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. Aids 2003; 17: 2437-2444.
18. Miserez AR, Muller PY, Spaniol V. Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. Aids 2002; 16: 1587-1594.
19. Miserez AR, Muller PY, Barella L, Schwietert M, Erb P, Vernazza PL, Battegay M. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. Aids 2001; 15: 2045-2049.
20. Nolan D, Moore C, Castley A, Sayer D, Mamotte C, John M, James I, Mallal S. Tumour necrosis factor-alpha gene-238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. Aids 2003; 17: 121-123.
21. Lindegaard B, Hansen AB, Gerstoft J, Pedersen BK. High Plasma Level of Interleukin-18 in HIV-Infected Subjects With Lipodystrophy. J Acquir Immune Defic Syndr 2004; 36: 588-593.
22. Volokhov D, Chizhikov V, Chumakov K, Rasooly A. Microarray analysis of erythromycin resistance determinants. J Appl Microbiol 2003; 95: 787-798.
23. Mongodin E, Finan J, Climo MW, Rosato A, Gill S, Archer GL. Microarray transcription analysis of clinical Staphylococcus aureus isolates resistant to vancomycin. J Bacteriol 2003; 185: 4638-4643.
24. Fitzgerald JR, Sturdevant DE, Mackie SM, Gill SR, Mußer JM. Evolutionary genomics of Staphylococcus aureus: insights into the origin of methicillin-resistant strains and the toxic shock syndrome epidemic. Proc Natl Acad Sci U S A 2001; 98: 8821-8826.
25. Krueger G, Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol 2004; 140: 218-225.
26. Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol 2004; 3: 315-318.
27. Mangge H, Gindl S, Kenzian H, Schauenstein K. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J Rheumatol 2003; 30: 2506-2507.
28. Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 2003; 49: 160-161.
29. Elliott K, Fitzpatrick E, Hill D, Brown J, Adams S, Chee P, Stewart G, Fulcher D, Tang M, Kemp A, King E, Varigos G, Bahlo M, Forrest S. The -590C/T and -34C/T interleukin-4 promoter polymorphisms are not associated with atopic eczema in childhood. J Allergy Clin Immunol 2001; 108: 285-287.
30. Söderhäll C, Bradley M, Kockum I, Luthman H, Wahlgren CF, Nordenskjöld M. Analysis of association and linkage for the interleukin-4 and interleukin-4 receptor b;alpha; regions in Swedish atopic dermatitis families. Clin Exp Allergy 2002; 32: 1199-1202.
31. Rafatpanah H, Bennett E, Pravica V, McCoy MJ, David TJ, Hutchinson IV, Arkwright PD. Association between novel GM-CSF gene polymorphisms and the frequency and severity of atopic dermatitis. J Allergy Clin Immunol 2003; 112: 593-598.
32. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.